Atyr PHARMA INC (NASDAQ:ATYR) Sees Significant Increase in Short Interest

Atyr PHARMA INC (NASDAQ:ATYR) saw a significant increase in short interest in December. As of December 15th, there was short interest totalling 2,920,000 shares, an increase of 34.6% from the November 30th total of 2,170,000 shares. Based on an average trading volume of 988,700 shares, the short-interest ratio is currently 3.0 days. Currently, 3.6% of the shares of the company are sold short.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Wells Fargo & Company initiated coverage on Atyr PHARMA in a research report on Friday, October 4th. They issued an “overweight” rating and a $17.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Atyr PHARMA in a report on Tuesday, December 10th. Finally, Jefferies Financial Group began coverage on shares of Atyr PHARMA in a research report on Thursday, September 5th. They set a “buy” rating and a $9.00 target price for the company.

Atyr PHARMA Trading Down 0.8 %

Shares of ATYR stock traded down $0.03 during trading on Friday, reaching $3.74. 1,046,593 shares of the company’s stock traded hands, compared to its average volume of 603,420. Atyr PHARMA has a 1 year low of $1.38 and a 1 year high of $3.98. The company has a market capitalization of $313.94 million, a P/E ratio of -3.98 and a beta of 1.07. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. The stock has a 50-day moving average price of $3.26.

Atyr PHARMA (NASDAQ:ATYR) last posted its earnings results on Thursday, November 7th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). As a group, sell-side analysts predict that Atyr PHARMA will post -0.89 earnings per share for the current fiscal year.

Atyr PHARMA Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.